BioAtla outlines progress

 

• Mecbotamab vedotin (BA3011) Phase 2 part 1 interim results in NSCLC continue to show antitumor activity with additional patients enrolled
  
  

• BA3011 Undifferentiated Pleomorphic Sarcoma (UPS) enrollment in Phase 2 part 2 of study anticipated to begin by year-end
  
  

• CAB-CTLA-4 (BA3071) Phase 1 study ongoing in tumor types responsive to CTLA-4 inhibition with first two cohorts completed without Dose Limiting Toxicities (DLTs) or Serious Adverse Events (SAEs) reported; third cohort (70mg) on-going with DLT observation period anticipated to conclude by year-end
  
  

• BA3182, CAB-EpCAMxCAB-CD3 bispecific T-cell engager (TCE) IND submission anticipated by year-end
  
  

• Cash balance of $178.1 million at quarter-end expected to provide funding into 2H24
  
  

• Management to host conference call and webcast today at 4:30 PM Eastern Time

Conference Call and Webcast Details
The management of BioAtla, Inc. will host a conference call and webcast for the investment community today, November 3, 2022, at 4:30 pm Eastern Time. A live webcast may be accessed here: https://viavid.webcasts.com/starthere.jsp?ei=1572537&tp_key=6d10a8eb15. The conference call can be accessed by dialing toll-free (844) 826-3035. The passcode for the conference call is 10171336.

A replay of the webcast and slides with topline interim clinical data referenced on the call will be available through “Events & Presentations” in the Investors section of the company’s website after the conclusion of the presentation and will be archived on the BioAtla website for one year.

https://finance.yahoo.com/news/bioatla-reports-third-quarter-2022-200100189.html